Seberb 250 - Tablet Gefitinib - 250mg 1 Tablet(s) / Tablet Genvio Pharma Ltd. Introduction: Seberb 250 is used in the treatment of non-small cell lung cancer. It is used in patients in which it has spread to other parts of the body, who have abnormal epidermal growth factor receptor (EGFR) genes, and who have not had previous treatment for cancer. Seberb 250 can be taken with or without food, but better to have it same time every day for better results. You should continue to take it as long as your doctor advises for it. The duration of treatment varies according to your need and response to treatment. You should take it exactly as... Uses of Seberb 250: Non-small cell lung cancer Side effects of Seberb 250: DiarrheaDry skinLoss of appetiteNauseaRashStomatitis (Inflammation of the mouth)VomitingWeakness How to use Seberb 250: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Seberb 250 may be taken with or without food, but it is better to take it at a fixed time. How Seberb 250 works: Seberb 250 is an anti-cancer medication. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells. What if you forget to take Seberb 250?: If you miss a dose of Seberb 250, skip it and continue with your normal schedule. Do not double the dose. Indication: Non-small Cell Lung Cancer Administration: Film-coated tab: May be taken with or without food. May also be dispersed in ½ glass of plain, non-carbonated water. No other liqd should be used. Drop the tab in water & stir w/o crushing until it disperses (approx 10 min). Drink immediately. Rinse glass w/ another ½ glass of water & drink. Dispersed liqd may also be administered via NG tube. Adult Dose: Oral Locally advanced or metastatic non-small cell lung carcinoma Adult: 250 mg once daily until disease progression or unacceptable toxicity Contraindication: Hypersensitivity. Lactation. Mode of Action: Gefitinib is a synthetic anilinoquinazoline which inhibits the intracellular phosphorylation of numerous tyrosine kinases associated w/ transmembrane cell surface receptors found on both normal and cancer cells, including epidermal growth factor receptor (EGFR) tyrosine kinase. Tyrosine kinase activity appears to be essentially important to cell proliferation and survival. Precaution: Patients w/ concurrent idiopathic pulmonary fibrosis, acute onset or worsening pulmonary or eye symptoms. Renal and hepatic impairment. Pregnancy. Monitoring Parameters Monitor liver function, prothrombin time or INR frequently. Lactation Unknown if distributed in human breast milk; not recommended Side Effect: >10% Skin reactions, all grades (47%),Diarrhea, all grades (29%),Decreased appetite, all grades (17%),Vomiting, all grades (14%),Increased ALT, all grades (11.4%) 1-10% Increased AST, all grades (7.9%),Stomatitis, all grades (7%),Conjunctivitis, blepharitis, and dry eye (6.7%),Conjunctivitis/blepharitis/dry eye (6%),Increased ALT, grades 3-4 (5.1%),Nail disorders, all grades (5%),Diarrhea, grades 3-4 (3%),Increased AST, grades 3-4 (3%),Increased bilirubin, all grades (2.7%),Decreased appetite, grades 2-3 (2.3%),Skin reactions, grades 3-4 (2%),Interstitial lung disease, all grades (1.3%),Vomiting, grades 3-4 (1.2%) <1% Interstitial lung disease, grades 3-4 (0.7%),Increased bilirubin, grades 3-4 (0.7%),Stomatitis, all grades (0.3%),Corneal erosion and aberrant eyelash growth (0.2%),Nail disorders, grades 3-4 (0.1%),Gastrointestinal perforation (0.1%),Ocular keratitis (0.1%),Erythema multiforme... Interaction: Concomitant use w/ CYP3A4 inducers (e.g. rifampicin, phenytoin, carbamazepine, barbiturates) may reduce serum gefitinib levels. Plasma concentrations may be increased w/ potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole). Increased INR or bleeding events w/ warfarin. May increase plasma levels of metoprolol. May exacerbate vinorelbine-induced neutropenia. Decreased plasma levels and potential reduction in efficacy w/ drugs that affect gastric pH (e.g. PPIs, H2-receptor antagonists).